Government ❯ Regulation ❯ FDA

Drug Approval

Mifepristone Compounding Pharmacies Safety Communications Patient Safety NDA Clinical Trials Labeling Changes Agricultural Products Animal Health Solutions Sunscreen Ingredients Wegovy Pill Compounded Medications Exdensur Telehealth Public Health Breakthrough Therapy Designation Marketing Violations Environmental Impact Studies Advertising Standards Psychedelic Medications Psychedelic Drug Healthcare Policies Mifepristone Approval Public Health Safety New Drug Application

FDA Warns ImmunityBio Over Anktiva Ads, Citing Misleading Cancer Claims

The company must submit a corrective plan within 15 business days.

Compass Pathways’ Psilocybin Therapy Hits Phase 3 Goal in Treatment-Resistant Depression

FDA Clears GSK’s Exdensur as First Twice-Yearly Add-On for Severe Eosinophilic Asthma

FDA Proposes Adding Bemotrizinol to U.S. Sunscreens, Invites Public Comment

FDA Grants Conditional Approval to Exzolt Cattle-CA1 for Screwworm and Cattle Fever Tick

FDA Investigates Fatal Liver Failures Linked to Sarepta’s Elevidys Therapy

Democratic-Led States Petition FDA to Remove Mifepristone Restrictions